Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (AMRS) is frequently featured in news coverage for its activities as a vertically integrated synthetic biology company focused on sustainable ingredients produced via precision fermentation. Company announcements highlight developments across its Lab-to-Market™ technology platform, industrial biomanufacturing assets, strategic partnerships, and financial and operational restructuring efforts.
News about Amyris often covers its strategic transformation initiatives, including programs aimed at cost reduction, portfolio simplification, and changes to its capital structure and liquidity. The company has publicly discussed a transformation program supported by external advisors, as well as the establishment of internal governance structures to oversee these efforts. A significant news event was the commencement of voluntary Chapter 11 proceedings by Amyris and certain domestic subsidiaries, described as a step to facilitate an operational and financial restructuring centered on its core sustainable ingredients business.
Investors and observers can also find updates on Amyris’ industrial biotechnology operations, such as its precision fermentation plant in Barra Bonita, Brazil. Recent news includes Amyris taking full ownership of this plant, investing in additional fermentation capacity, and winding down a joint venture while retaining manufacturing assets and royalty interests related to specific fermented ingredients.
Another recurring theme in Amyris news is the formation and evolution of strategic partnerships and licensing agreements. Press releases describe exclusive licenses for cosmetic ingredients, long-term manufacturing agreements, and collaborations for sustainable squalene and fermented sweetener technologies. Earnings updates and revenue guidance communications provide additional context on how these partnerships, ingredient sales, and technology access activities fit into the company’s broader strategic agenda.
This news page aggregates such company-issued releases and related coverage, offering a centralized view of key developments in Amyris’ synthetic biology, fermentation, partnership, and restructuring activities over time.
Amyris, a synthetic biotechnology company, reported Q4 2022 Consumer revenue of $52.8 million, marking a 64% increase year-over-year, contributing to full-year Consumer revenue of $176.9 million, up 92%. Core revenue reached $75.8 million in Q4, a 17% increase, with full-year Core revenue at $269.8 million, growing 44%. The company improved cash usage for operating and investing activities sequentially each quarter, reducing cash use from $200 million in Q1 to $97 million in Q4. Significant capital financing of $200 million was secured, and strategic partnerships were expanded. Despite challenges in Technology Access revenue and increased cash operating expenses, Amyris aims for profitability and self-sufficiency by end of 2023.
Amyris, Inc. (Nasdaq: AMRS) announced it will release its financial results for the fourth quarter and full year ended December 31, 2022, on March 15, 2023, post-market close. CEO John Melo and CFO Han Kieftenbeld will lead a conference call at 1:30 p.m. PT (4:30 p.m. ET) to discuss the results and provide a business update. Participants can access the call via the company's Investor Relations website or by phone at (844) 850-0551.
Amyris focuses on sustainable health and beauty products and holds a proprietary Lab-to-Market™ technology, serving over 300 million consumers through more than 20,000 products.
On February 28, 2023, Alisa Volkman and Naomi Watts announced The New Pause, a symposium focused on menopause, scheduled for March 11, 2023, in Santa Monica, California. Building on their successful NYC event, the symposium aims to destigmatize menopause and empower women with knowledge. Key topics include biology, relationships, and health during menopause, featuring experts like Dr. Avrum Bluming and Molly Ringwald. The event reflects a growing momentum in discussing menopause, highlighting the importance of dialogue and expert insights.
On February 22, 2023, Amyris (NASDAQ: AMRS) announced a strategic agreement with Givaudan, acquiring significant cosmetic ingredients such as Neossance® Squalane and Hemisqualane. This partnership aims to strengthen their leadership in biofermentation-based chemistry within the beauty industry as part of Givaudan's 2025 strategy. The deal includes an upfront cash payment, performance-based earnouts, and a manufacturing agreement. The acquisition is expected to add approximately USD 30 million in sales to Givaudan's results for 2022. Regulatory approvals are pending for the transaction.
Amyris, Inc. (Nasdaq: AMRS) has launched a new haircare line, 4U by Tia, in collaboration with actress Tia Mowry, now available exclusively at Walmart. This line features eight products designed for textured hair (2A to 4C) and incorporates Amyris' patented ingredient, Hemi15, which is 100% vegan and free from silicones, sulfates, and parabens. The collaboration marks Amyris' fifth consumer brand introduced in Walmart stores, aimed at providing affordable clean beauty options while promoting sustainability. However, the company faces risks including market volatility and supply chain disruptions that could impact operations.
Amyris, a synthetic biotechnology company (Nasdaq: AMRS), will present at the 41st Annual J.P. Morgan Health Care Conference on January 11, 2023, at 11:15 am PT in San Francisco. This event showcases Amyris's focus on sustainable consumption through its Lab-to-Market™ technology. A live webcast and replay will be accessible via the company's Investor Relations section. Amyris specializes in creating sustainable ingredients for health, beauty, and flavor markets, reaching over 300 million consumers globally.
Amyris, Inc. (Nasdaq: AMRS) has announced a registered direct offering of 20 million shares and warrants to purchase up to 15 million additional shares at a combined price of $1.50 per share. Concurrently, a private placement with Foris Ventures involves 13.33 million shares and warrants for 10 million shares, also priced at $1.50. The company expects gross proceeds of approximately $50 million to be used for general corporate purposes. The offerings are set for closing around December 30, 2022, subject to standard conditions.
Amyris, Inc. (Nasdaq: AMRS) has finalized key financial terms for a strategic transaction valued at over $500 million for exclusive rights to supply two ingredients. This transaction is pending antitrust review under the Hart-Scott-Rodino Act, with expectations to close in early Q1 2023. As part of the deal, Amyris will maintain the development and manufacturing of these ingredients, while also entering a long-term R&D collaboration. The company is optimistic about continued growth in its core business and the strategic value of this partnership.
Amyris, Inc. (Nasdaq: AMRS) reported an impressive 80% year-over-year growth in its direct-to-consumer sales during Cyber Monday on November 28, 2022. This growth is assessed based on a like-for-like comparison with the same period last year. CEO John Melo expressed satisfaction with the ongoing strong momentum across its consumer brands and overall business. The sales performance continues from a successful Black Friday week, indicating robust consumer interest in Amyris's sustainable products.
Amyris, a synthetic biotechnology company, announced record consumer sales for Black Friday week, from November 18 to November 26, 2022. The company experienced significant DTC sales growth, especially with its Biossance brand, which is projected to achieve $20 million in sales this month. Other brands like JVN and Rose Inc. reported over 400% DTC revenue growth compared to last year. CEO John Melo highlighted strong consumer demand for sustainable products and an effective omnichannel strategy, indicating a robust performance ahead.
